Table 2. Assessment of cure by benznidazole (Bz) and posaconazole (Ps), administered in monotherapy or concomitant combinations, in a murine model of Trypanosoma cruzi infection¹.

Experimental groups	Number of surviving/total number of animals	Number of negative FBE2/number of mice	Number of negative blood PCR3 sample/number of mice	Total of negative assays/number of mice
Uninfected	10/10	10/10	10/10	10/10
Untreated	4/10	0/6	0/6	0/6
Bz 100 mg/Kg/day	10/10	0/10	0/10	0/10
Ps 40 mg/Kg/day	10/10	1/10	0/1	0/10
Bz+Ps (100+20 mg/Kg/day)	10/10	5/10	3/5	3/10
Bz+Ps (50+20 mg/Kg/day)	10/10	0/10	0/10	0/10
Bz+Ps (100+10 mg/Kg/day)	10/10	5/10	2/5	2/10
Bz+Ps (50+10 mg/Kg/day)	10/10	0/10	0/10	0/10

¹Swiss female (n = 10) weight 20 to 24 g were inoculated with 5×10³ trypomastigotes (VL-10 strain).

Treatment was initiated at 7^th day after inoculation followed by 20 days and the drugs were administered orally. Benznidazole was given once daily and posaconazole administered twice a day (b.i.d.).

²FBE – fresh blood examination performed before and after cyclophosphamide immunosuppression.

³PCR assay was performed in the 1^st and 6^th month after treatment.